{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:23:07Z","timestamp":1790742187587,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The management of behavioral symptoms and rigidity in patients with dementia constitutes a significant challenge. Short-term studies suggest an interest in the use of medical cannabis, but long-term data are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study was to investigate the feasibility and long-term safety of administering tetrahydrocannabinol\/cannabidiol (THC\/CBD) treatment as an additional drug to a poly medicated population with severe dementia, evaluate clinical improvements, and collect information on the pharmacokinetics of cannabinoids and possible drug\u2013drug interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective observational study of patients with severe dementia living in a long-term care home to whom the physicians had prescribed a medical cannabis treatment. Data were collected over 2 years. We assessed the changes in medical cannabis dosages, safety parameters, variations in neuropsychiatric problems, agitation, rigidity, the most invalidating daily activity, and disabling behavior trouble scores. We evaluated the pharmacokinetics of cannabinoids by measuring plasma levels and analyzing the enzymatic activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We assessed 19 patients (81.4 years\u201417 women and two men) receiving an average of 12.4 mg THC\/24.8 mg CBD per day for up to 13 months, with no reported problems related to the treatment and limited adverse drug reactions. Clinical scores showed a marked improvement that was stable over time, deprescription of other medications, and care facilitated. The pharmacokinetic evaluation showed an expected slight reduction in the enzymatic activity of CYP1A2 and CYP2C19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A long-term THC\/CBD (1:2) medication can be administered safely and with overall positive clinical improvement to poly medicated older adults with severe dementia and associated problems. The results must be confirmed in a randomized trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2022.957665","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T07:38:55Z","timestamp":1664437135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Sophie","family":"Pautex","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Daali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Augsburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"de Saussure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wampfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Desmeules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Broers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1007\/s00213-015-3889-y","article-title":"Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.","volume":"232","author":"Ahmed","year":"2015","journal-title":"Psychopharmacology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6010003","article-title":"Medicinal Cannabis-potential drug interactions.","volume":"6","author":"Alsherbiny","year":"2018","journal-title":"Medicines"},{"key":"B3","year":"2021","journal-title":"World Alzheimer report 2021."},{"key":"B4","first-page":"142","article-title":"Synthetic cannabinoids in dementia with agitation: Case studies.","volume":"10","author":"Amanullah","year":"2013","journal-title":"Clin. Neuropsychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00037","article-title":"Cannabinoids for treatment of Alzheimer\u2019s disease: Moving toward the clinic.","volume":"5","author":"Aso","year":"2014","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0706743719892717","article-title":"Cannabinoids for the neuropsychiatric symptoms of dementia: A systematic review and meta-analysis.","volume":"65","author":"Bahji","year":"2020","journal-title":"Can. J. Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/gps.490","article-title":"The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer\u2019s disease patients.","volume":"17","author":"Beeri","year":"2002","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/bcpt.12586","article-title":"Evaluation of mutual drug-drug interaction within Geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method.","volume":"119","author":"Bosilkovska","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/clpt.2014.83","article-title":"Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.","volume":"96","author":"Bosilkovska","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000498924","article-title":"Prescription of a THC\/CBD-based medication to patients with dementia: A pilot study in Geneva.","volume":"2","author":"Broers","year":"2019","journal-title":"Med. Cannabis Cannabinoids"},{"key":"B11","article-title":"Behavioral and psychological symptoms of dementia- StatPearl 2021","author":"Cloak","year":"2021","journal-title":"StatPearls [Internet]"},{"key":"B12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1053\/SCNP00100325","article-title":"Agitation: Subtypes and their mechanisms.","volume":"1","author":"Cohen-Mansfield","year":"1996","journal-title":"Semin. Clin. Neuropsychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11940-012-0166-9","article-title":"Treatment of behavioral and psychological symptoms of Alzheimer\u2019s disease.","volume":"14","author":"Corbett","year":"2012","journal-title":"Curr. Treat. Options Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/wnl.44.12.2308","article-title":"The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia.","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.05.014","article-title":"Fitness to drive and cannabis: Validation of two blood THCCOOH thresholds to discriminate occasional users from heavy smokers.","volume":"242","author":"Fabritius","year":"2014","journal-title":"Forensic Sci. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9791","DOI":"10.1007\/s00216-013-7412-1","article-title":"Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.","volume":"405","author":"Fabritius","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1476-5381.2010.00776.x","article-title":"How important are sex differences in cannabinoid action?","volume":"160","author":"Fattore","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/s0379-0738(01)00538-2","article-title":"\u03949-THC, 11-OH-\u03949-THC and \u03949-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people.","volume":"123","author":"Giroud","year":"2001","journal-title":"Forensic Sci. Int."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619846993","article-title":"Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: A systematic review.","volume":"10","author":"Hillen","year":"2019","journal-title":"Ther. Adv. Drug Saf."},{"key":"B20","year":"2022","journal-title":"Welcome to the ICH official website."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00275","article-title":"Healthy aging and dementia: Two roads diverging in midlife?","volume":"10","author":"Irwin","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1517\/14728222.2012.671812","article-title":"The therapeutic potential of the endocannabinoid system for Alzheimer\u2019s disease.","volume":"16","author":"Karl","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"B23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40263-015-0270-y","article-title":"Cannabinoids for the treatment of agitation and aggression in Alzheimer\u2019s disease.","volume":"29","author":"Liu","year":"2015","journal-title":"CNS Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing.","volume":"49","author":"MacCallum","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4103\/sni.sni_45_18","article-title":"Review of the neurological benefits of phytocannabinoids.","volume":"9","author":"Maroon","year":"2018","journal-title":"Surg. Neurol. Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer\u2019s disease.","volume":"79","author":"Mart\u00edn-Moreno","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease. Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s disease.","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2013.00130","article-title":"Does cannabidiol protect against adverse psychological effects of THC?","volume":"4","author":"Niesink","year":"2013","journal-title":"Front. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/01.JGP.0000192478.82189.a8","article-title":"Mapping scores onto stages: Mini-mental state examination and clinical dementia rating.","volume":"14","author":"Perneczky","year":"2006","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B30","first-page":"61","author":"Prince","year":"2014","journal-title":"Dementia UK: Second edition\u2013overview."},{"key":"B31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3917\/psyt.252.0129","article-title":"Prescription de cannabis \u00e0 usage th\u00e9rapeutique pour les personnes \u00e2g\u00e9es atteintes de d\u00e9mence: L\u2019engouement des proches aidants.","volume":"25","author":"Revol","year":"2019","journal-title":"Psychotropes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/mds.870090114","article-title":"Interrater reliability of the unified Parkinson\u2019s disease rating scale motor examination.","volume":"9","author":"Richards","year":"1994","journal-title":"Mov. Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/wnl.43.2.250","article-title":"Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop.","volume":"43","author":"Rom\u00e1n","year":"1993","journal-title":"Neurology"},{"key":"B34","year":"2021","journal-title":"Summary of product characteristics."},{"key":"B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JAD-150915","article-title":"Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study.","volume":"51","author":"Shelef","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jama.293.5.596","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence.","volume":"293","author":"Sink","year":"2005","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/gps.1858","article-title":"Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The Cache County study.","volume":"23","author":"Steinberg","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review.","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/JPR.S240011","article-title":"Review of scientific evidence for THC:CBD oromucosal spray (Nabiximols) in the management of chronic pain.","volume":"13","author":"\u00dcberall","year":"2020","journal-title":"J. Pain Res."},{"key":"B40","year":"2022","journal-title":"The use of the WHO-UMC system for standardised case causality assessment."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jagp.2015.07.011","article-title":"Tetrahydrocannabinol in behavioral disturbances in dementia: A crossover randomized controlled trial.","volume":"23","author":"van den Elsen","year":"2015","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B42","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease.","volume":"12","author":"Volicer","year":"1997","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease.","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol."}],"updated-by":[{"DOI":"10.3389\/fnagi.2023.1176468","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000}}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.957665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T04:23:29Z","timestamp":1678335809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.957665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":43,"alternative-id":["10.3389\/fnagi.2022.957665"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.957665","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"957665"}}